An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

Ferenc G. Rick, Norman L Block, Andrew V Schally

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix is a third generation antagonist of luteinizing hormone-releasing hormone (LHRH, also termed gonadotropin-releasing hormone) for the first-line treatment of androgen-dependent advanced prostate cancer. Degarelix acts directly on the pituitary receptors for LHRH, blocking the action of endogenous LHRH. The use of degarelix eliminates the initial undesirable surge in gonadotropin and testosterone levels, which is produced by agonists of LHRH. Degarelix is the most comprehensively studied and widely available LHRH antagonist worldwide. Clinical trials have demonstrated that degarelix has a long-term efficacy similar to the LHRH agonist leuprolide in achieving testosterone suppression in patients with prostate cancer. Degarelix, however, produces a faster suppression of testosterone and prostate-specific antigen (PSA), with no testosterone surges or microsurges, and thus prevents the risk of clinical flare in advanced disease. Recent clinical trials demonstrated that treatment with degarelix results in improved disease control when compared with an LHRH agonist in terms of superior PSA progression-free survival, suggesting that degarelix likely delays progression to castration-resistant disease and has a more significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone. Degarelix is usually well tolerated, with limited toxicity and no evidence of systemic allergic reactions in clinical studies. Degarelix thus represents an important addition to the hormonal armamentarium for therapy of advanced androgen-dependent prostate cancer. 2013 Rick et al, publisher and licensee Dove Medical Press Ltd.

Original languageEnglish
Pages (from-to)391-402
Number of pages12
JournalOncoTargets and Therapy
Volume6
DOIs
StatePublished - Apr 23 2013

Fingerprint

Prostatic Neoplasms
Gonadotropin-Releasing Hormone
Hormones
Androgens
Testosterone
Therapeutics
Prostate-Specific Antigen
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
Clinical Trials
Leuprolide
LHRH Receptors
Castration
Follicle Stimulating Hormone
Gonadotropins
Disease-Free Survival
Alkaline Phosphatase
Hypersensitivity
Psychology
Bone and Bones
Serum

Keywords

  • Androgen-dependent prostate cancer
  • Degarelix
  • GnRH
  • Hormonal therapy
  • LHRH
  • Metastatic prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. / Rick, Ferenc G.; Block, Norman L; Schally, Andrew V.

In: OncoTargets and Therapy, Vol. 6, 23.04.2013, p. 391-402.

Research output: Contribution to journalArticle

@article{d7638ae020504f1ca391029f35766187,
title = "An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer",
abstract = "Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix is a third generation antagonist of luteinizing hormone-releasing hormone (LHRH, also termed gonadotropin-releasing hormone) for the first-line treatment of androgen-dependent advanced prostate cancer. Degarelix acts directly on the pituitary receptors for LHRH, blocking the action of endogenous LHRH. The use of degarelix eliminates the initial undesirable surge in gonadotropin and testosterone levels, which is produced by agonists of LHRH. Degarelix is the most comprehensively studied and widely available LHRH antagonist worldwide. Clinical trials have demonstrated that degarelix has a long-term efficacy similar to the LHRH agonist leuprolide in achieving testosterone suppression in patients with prostate cancer. Degarelix, however, produces a faster suppression of testosterone and prostate-specific antigen (PSA), with no testosterone surges or microsurges, and thus prevents the risk of clinical flare in advanced disease. Recent clinical trials demonstrated that treatment with degarelix results in improved disease control when compared with an LHRH agonist in terms of superior PSA progression-free survival, suggesting that degarelix likely delays progression to castration-resistant disease and has a more significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone. Degarelix is usually well tolerated, with limited toxicity and no evidence of systemic allergic reactions in clinical studies. Degarelix thus represents an important addition to the hormonal armamentarium for therapy of advanced androgen-dependent prostate cancer. 2013 Rick et al, publisher and licensee Dove Medical Press Ltd.",
keywords = "Androgen-dependent prostate cancer, Degarelix, GnRH, Hormonal therapy, LHRH, Metastatic prostate cancer",
author = "Rick, {Ferenc G.} and Block, {Norman L} and Schally, {Andrew V}",
year = "2013",
month = "4",
day = "23",
doi = "10.2147/OTT.S32426",
language = "English",
volume = "6",
pages = "391--402",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

AU - Rick, Ferenc G.

AU - Block, Norman L

AU - Schally, Andrew V

PY - 2013/4/23

Y1 - 2013/4/23

N2 - Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix is a third generation antagonist of luteinizing hormone-releasing hormone (LHRH, also termed gonadotropin-releasing hormone) for the first-line treatment of androgen-dependent advanced prostate cancer. Degarelix acts directly on the pituitary receptors for LHRH, blocking the action of endogenous LHRH. The use of degarelix eliminates the initial undesirable surge in gonadotropin and testosterone levels, which is produced by agonists of LHRH. Degarelix is the most comprehensively studied and widely available LHRH antagonist worldwide. Clinical trials have demonstrated that degarelix has a long-term efficacy similar to the LHRH agonist leuprolide in achieving testosterone suppression in patients with prostate cancer. Degarelix, however, produces a faster suppression of testosterone and prostate-specific antigen (PSA), with no testosterone surges or microsurges, and thus prevents the risk of clinical flare in advanced disease. Recent clinical trials demonstrated that treatment with degarelix results in improved disease control when compared with an LHRH agonist in terms of superior PSA progression-free survival, suggesting that degarelix likely delays progression to castration-resistant disease and has a more significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone. Degarelix is usually well tolerated, with limited toxicity and no evidence of systemic allergic reactions in clinical studies. Degarelix thus represents an important addition to the hormonal armamentarium for therapy of advanced androgen-dependent prostate cancer. 2013 Rick et al, publisher and licensee Dove Medical Press Ltd.

AB - Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix is a third generation antagonist of luteinizing hormone-releasing hormone (LHRH, also termed gonadotropin-releasing hormone) for the first-line treatment of androgen-dependent advanced prostate cancer. Degarelix acts directly on the pituitary receptors for LHRH, blocking the action of endogenous LHRH. The use of degarelix eliminates the initial undesirable surge in gonadotropin and testosterone levels, which is produced by agonists of LHRH. Degarelix is the most comprehensively studied and widely available LHRH antagonist worldwide. Clinical trials have demonstrated that degarelix has a long-term efficacy similar to the LHRH agonist leuprolide in achieving testosterone suppression in patients with prostate cancer. Degarelix, however, produces a faster suppression of testosterone and prostate-specific antigen (PSA), with no testosterone surges or microsurges, and thus prevents the risk of clinical flare in advanced disease. Recent clinical trials demonstrated that treatment with degarelix results in improved disease control when compared with an LHRH agonist in terms of superior PSA progression-free survival, suggesting that degarelix likely delays progression to castration-resistant disease and has a more significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone. Degarelix is usually well tolerated, with limited toxicity and no evidence of systemic allergic reactions in clinical studies. Degarelix thus represents an important addition to the hormonal armamentarium for therapy of advanced androgen-dependent prostate cancer. 2013 Rick et al, publisher and licensee Dove Medical Press Ltd.

KW - Androgen-dependent prostate cancer

KW - Degarelix

KW - GnRH

KW - Hormonal therapy

KW - LHRH

KW - Metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84876300040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876300040&partnerID=8YFLogxK

U2 - 10.2147/OTT.S32426

DO - 10.2147/OTT.S32426

M3 - Article

C2 - 23620672

AN - SCOPUS:84876300040

VL - 6

SP - 391

EP - 402

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -